1 |
Anstead GM, Carlson KE, Katzenellenbogen JA (1997). The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids, 62, 268-303.
DOI
|
2 |
Arnal JF, Valera MC, Payrastre B, et al (2012). Structure-function relationship of estrogen receptors in cardiovascular pathophysiological models. Thromb Res, 130, 7-11.
DOI
|
3 |
Ascenzi P, Bocedi A, Marino M (2006). Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med, 27, 299-402.
DOI
|
4 |
LaFrate AL, Carlson KE, Katzenellenbogen JA (2009). Steroidal bivalent ligands for the estrogen receptor: design, synthesis, characterization and binding affinities. Bioorg Med Chem, 17, 3528-35.
DOI
|
5 |
Leinonen R, Nardone F, Zhu W, et al (2006). UniSave: the UniProtKB sequence/annotation version database. Bioinformatics, 22, 1284-5.
DOI
|
6 |
Lewis DF, Ogg MS, Goldfarb PS, et al (2002). Molecular modelling of the human glucocorticoid receptor (hGR) ligand-binding domain (LBD) by homology with the human estrogen receptor alpha (hERalpha) LBD: quantitative structure-activity relationships within a series of CYP3A4 inducers where induction is mediated via hGR involvement. J Steroid Biochem Mol Biol, 82, 195-9.
DOI
|
7 |
Li X, Huang J, Yi P, et al (2004). Single-chain estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways. Mol Cell Biol, 24, 7681-94.
DOI
|
8 |
Madeira KP, Daltoe RD, Sirtoli GM, et al (2012). Comparison of immunohistochemical analysis with estrogen receptor SP1 and 1D5 monoclonal antibodies in breast cancer. Pathol Res Pract, 208, 657-61.
DOI
|
9 |
Maggiolini M, Bonofiglio D, Marsico S, et al (2001). Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol, 60, 595-602.
|
10 |
Meshram RJ, Bhiogade NH, Gacche RN, et al (2012). Virtual screening and docking exploration on estrogen receptor: An in silico approach to decipher novel anticancer agents. Indian J Biotechnol, 11, 389-95.
|
11 |
Millanta F, Calandrella M, Bari G, et al (2005). Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues. Res Vet Sci, 79, 225-32.
DOI
|
12 |
Zhang X, Spiegelman D, Baglietto L, et al (2012). Carotenoid intakes and risk of breast cancer defined by estrogen receptor and progesterone receptor status: a pooled analysis of 18 prospective cohort studies. Am J Clin Nutr, 95, 713-25.
DOI
|
13 |
Tremollieres F, Lopes P (2002). [Specific estrogen receptor modulators (SERMs)]. Presse Med, 31, 1323-8.
|
14 |
UniProt C (2014). Activities at the Universal Protein Resource (UniProt). Nucleic Acids Res, 42, 191-8.
DOI
|
15 |
Xu CY, Jiang ZN, Zhou Y, et al (2013). Estrogen receptor alpha roles in breast cancer chemoresistance. Asian Pac J Cancer Prev, 14, 4049-52.
DOI
ScienceOn
|
16 |
Brzozowski AM, Pike AC, Dauter Z, et al (1997). Molecular basis of agonism and antagonism in the oestrogen receptor. Nature, 389, 753-8.
DOI
|
17 |
Barkhem T, Carlsson B, Nilsson Y, et al (1998). Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol, 54, 105-12.
|
18 |
Berman HM, Westbrook J, Feng Z, et al (2000). The Protein Data Bank. Nucleic Acids Res, 28, 235-42.
DOI
|
19 |
Bollig-Fischer A, Thakur A, Sun Y, et al (2012). The Predominant Proteins that React to the MC-20 Estrogen Receptor Alpha Antibody Differ in Molecular Weight between the Mammary Gland and Uterus in the Mouse and Rat. Int J Biomed Sci, 8, 51-63.
|
20 |
Cao X, Jiang J, Zhang S, et al (2013). Discovery of natural estrogen receptor modulators with structure-based virtual screening. Bioorg Med Chem Lett, 23, 3329-33.
DOI
|
21 |
Chakraborty S, Cole S, Rader N, et al (2012). In silico design of peptidic inhibitors targeting estrogen receptor alpha dimer interface. Mol Divers, 16, 441-51.
DOI
|
22 |
Chitrala KN, Yeguvapalli S (2013). Prediction and analysis of ligands against estrogen related receptor alpha. Asian Pac J Cancer Prev, 14, 2371-5.
DOI
|
23 |
Czeczuga-Semeniuk E, Jarzabek K, Lemancewicz D, et al (2009). The vitamin A family can significantly decrease the expression of ERbeta of ERs positive breast cancer cells in the presence or absence of ER ligands and paclitaxel. Gynecol Endocrinol, 25, 287-93.
DOI
|
24 |
D'Amelio P, Isaia GC (2013). The use of raloxifene in osteoporosis treatment. Expert Opin Pharmacother, 14, 949-56.
DOI
|
25 |
Osborne CK, Zhao H, Fuqua SA (2000). Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol, 18, 3172-86.
|
26 |
Nam K, Marshall P, Wolf RM, et al (2003). Simulation of the different biological activities of diethylstilbestrol (DES) on estrogen receptor alpha and estrogen-related receptor gamma. Biopolymers, 68, 130-8.
DOI
|
27 |
Nam KH, Huang Q, Ke A (2012). Nucleic acid binding surface and dimer interface revealed by CRISPR-associated CasB protein structures. FEBS Lett, 586, 3956-61.
DOI
|
28 |
Nose T, Tokunaga T, Shimohigashi Y (2009). Exploration of endocrine-disrupting chemicals on estrogen receptor alpha by the agonist/antagonist differential-docking screening (AADS) method: 4-(1-adamantyl)phenol as a potent endocrine disruptor candidate. Toxicol Lett, 191, 33-9.
DOI
|
29 |
Pieper U, Eswar N, Braberg H, et al (2004). MODBASE, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res, 32, 217-22.
|
30 |
Pike AC, Brzozowski AM, Hubbard RE, et al (1999). Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J, 18, 4608-18.
DOI
|
31 |
Rehm S, Solleveld HA, Portelli ST, et al (2007). Histologic changes in ovary, uterus, vagina, and mammary gland of mature beagle dogs treated with the SERM idoxifene. Birth Defects Res B Dev Reprod Toxicol, 80, 225-32.
DOI
|
32 |
Rustici G, Kolesnikov N, Brandizi M, et al (2013). ArrayExpress update--trends in database growth and links to data analysis tools. Nucleic Acids Res, 41, 987-90.
DOI
|
33 |
Gangloff M, Ruff M, Eiler S, et al (2001). Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism. J Biol Chem, 276, 15059-65.
DOI
|
34 |
de Villiers TJ, Gass ML, Haines CJ, et al (2013). Global Consensus Statement on menopausal hormone therapy. Maturitas, 74, 391-2.
DOI
|
35 |
Eliassen AH, Hendrickson SJ, Brinton LA, et al (2012). Circulating carotenoids and risk of breast cancer: pooled analysis of eight prospective studies. J Natl Cancer Inst, 104, 1905-16.
DOI
|
36 |
Frasor J, Barnett DH, Danes JM, et al (2003). Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the uterus. Endocrinol, 144, 3159-66.
DOI
|
37 |
Gaudet P, Lane L, Fey P, et al (2009). Collaborative annotation of genes and proteins between UniProtKB/Swiss-Prot and dictyBase. Database (Oxford), 2009, 16.
|
38 |
Hendrickson SJ, Hazra A, Chen C, et al (2012). beta-Carotene 15,15'-monooxygenase 1 single nucleotide polymorphisms in relation to plasma carotenoid and retinol concentrations in women of European descent. Am J Clin Nutr, 96, 1379-89.
DOI
|
39 |
Illera JC, Perez-Alenza MD, Nieto A, et al (2006). Steroids and receptors in canine mammary cancer. Steroids, 71, 541-8.
DOI
|
40 |
Kuiper G, Carlsson B, Grandien K, et al (1997). Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinol, 138, 863-70.
|
41 |
Kumar R, Thompson EB (1999). The structure of the nuclear hormone receptors. Steroids, 64, 310-9.
DOI
|
42 |
Kumar R, Zakharov MN, Khan SH, et al (2011). The dynamic structure of the estrogen receptor. J Amino Acids, 2011, 812540.
|
43 |
Sievers F, Wilm A, Dineen D, et al (2011). Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol, 7, 539.
|
44 |
Rybalchenko V, Grillo MA, Gastinger MJ, et al (2009). The unliganded long isoform of estrogen receptor beta stimulates brain ryanodine receptor single channel activity alongside with cytosolic Ca2+. J Recept Signal Transduct Res, 29, 326-41.
DOI
|
45 |
Schnell S, Mendoza C (2001). A fast method to estimate kinetic constants for enzyme inhibitors. Acta Biotheor, 49, 109-13.
DOI
|
46 |
Shiau AK, Barstad D, Loria PM, et al (1998). The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell, 95, 927-37.
DOI
|
47 |
Stump AL, Kelley KW, Wensel TM (2007). Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis. Ann Pharmacother, 41, 833-9.
DOI
|
48 |
Suganya J, Radha M, Naorem DL, et al (2014). In Silico docking studies of selected flavonoids-- natural healing agents against breast cancer. Asian Pac J Cancer Prev, 15, 8155-9.
DOI
|
49 |
Thompson JD, Higgins DG, Gibson TJ (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res, 22, 4673-80.
DOI
|
50 |
Toniti W, Suthiyotha N, Puchadapirom P, et al (2011). Binding capacity of ER-alpha ligands and SERMs: comparison of the human, dog and cat. Asian Pac J Cancer Prev, 12, 2875-9.
|
51 |
Touraine P (2003). [SERMs and uterus]. Ann Med Interne (Paris), 154, 103-8.
|